Lee T H, Chan June, Lau Vivian W Y, Lee W L, Lau P C, Lo M H
Allergy Centre, Hong Kong Sanatorium and Hospital, 2 Village Road, Happy Valley, Hong Kong.
Department of Pathology, Hong Kong Sanatorium and Hospital, 2 Village Road, Happy Valley, Hong Kong.
Hong Kong Med J. 2014 Aug;20(4):325-30. doi: 10.12809/hkmj144243. Epub 2014 Jun 20.
Peanut allergy is one of the commonest food hypersensitivities causing fatal or near-fatal reactions. There is, currently, no preventive treatment and the incidence of severe allergic reactions during peanut desensitisation has limited its clinical use. Anti-immunoglobulin E therapy has been shown to be effective in preventing peanut-induced reactions but it does not result in long-term tolerance. Two important advances have recently been reported. One involves gradual oral introduction of peanut protein to desensitise, whereas the other approach uses a combination of anti-immunoglobulin E and oral peanut immunotherapy. Both approaches could offer a way to desensitise with a far greater margin of safety than has, hitherto, been reported. This article provides an overview of the literature on peanut immunotherapy and describes the experience in a small group of children in Hong Kong who were treated successfully using anti-immunoglobulin E combined with oral peanut desensitisation.
花生过敏是最常见的食物过敏之一,可引发致命或近乎致命的反应。目前尚无预防性治疗方法,且花生脱敏过程中严重过敏反应的发生率限制了其临床应用。抗免疫球蛋白E疗法已被证明在预防花生诱发的反应方面有效,但它并不能带来长期耐受性。最近有两项重要进展被报道。一种方法是逐步口服引入花生蛋白进行脱敏,而另一种方法则是将抗免疫球蛋白E与口服花生免疫疗法相结合。这两种方法都可能提供一种比迄今报道的更安全的脱敏方式。本文概述了关于花生免疫疗法的文献,并描述了香港一小群儿童使用抗免疫球蛋白E联合口服花生脱敏成功治疗的经验。